Valuation: Halozyme Therapeutics, Inc.

Market Cap 11.7B 10.12B 9.45B 8.67B 16.31B 1,114B 16.57B 111B 43.54B 558B 43.95B 42.99B 1,846B P/E 2026 *
13.8x
P/E 2027 * 11.1x
Enterprise Value 13.05B 11.29B 10.54B 9.67B 18.19B 1,242B 18.47B 124B 48.54B 622B 49B 47.92B 2,058B EV / Sales 2026 *
7.04x
EV / Sales 2027 * 5.86x
Free-Float
99%
Yield 2026 *
-
Yield 2027 * -
1 day+20.24%
1 week+24.93%
Current month+24.93%
1 month+28.31%
3 months+60.82%
6 months+26.95%
Current year+53.22%
1 week 81.75
Extreme 81.75
103.3
1 month 73.89
Extreme 73.8901
103.3
Current year 61.32
Extreme 61.325
103.3
1 year 61.22
Extreme 61.225
103.3
3 years 32.83
Extreme 32.83
103.3
5 years 29.85
Extreme 29.85
103.3
10 years 8.18
Extreme 8.18
103.3
Manager TitleAgeSince
Chief Executive Officer 63 2014-01-05
Director of Finance/CFO 61 2013-04-30
Director of Finance/CFO - 2026-06-07
Director TitleAgeSince
Director/Board Member 59 2013-03-27
Director/Board Member 63 2014-01-05
Chairman 61 -
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Fiscal year

Chief Executive Officer

5,769 0.0049%
7/1/26 Free

Executive/Senior Manager

56,055 0.0473%
7/1/26 Free

Chief Financial Officer

168,986 0.1425%
Change 5-day change 1-year change 3-year change Capi.($)
+20.24%+24.93%+63.94%+138.10% 11.7B
+0.16%-1.24%+59.35%+20.83% 317B
-1.03%+0.35%+32.89%-11.30% 72.2B
+1.29%-0.31%-4.34%-5.12% 8.45B
+2.28%+8.10%-14.26%-6.77% 4.75B
+14.37%+22.10%+4.25%+55.26% 4.38B
+3.60%+9.66%-28.04%+14.06% 4.26B
+1.88%+6.74%+15.55%+44.76% 2.77B
+4.26%+0.31%+1.17%-0.79% 2.26B
+9.74%+12.40%-14.54%+43.39% 1.95B
Average +5.68%+8.86%+11.60%+29.24% 43B
Weighted average by Cap. +0.81%+0.37%+50.62%+18.24%

Financials

2026 *2027 *
Net sales 1.85B 1.6B 1.5B 1.37B 2.58B 176B 2.62B 17.57B 6.9B 88.43B 6.96B 6.81B 292B 2.05B 1.77B 1.66B 1.52B 2.86B 195B 2.9B 19.43B 7.63B 97.82B 7.7B 7.53B 323B
Net income 869M 751M 702M 644M 1.21B 82.68B 1.23B 8.23B 3.23B 41.44B 3.26B 3.19B 137B 1.07B 924M 863M 791M 1.49B 102B 1.51B 10.12B 3.97B 50.94B 4.01B 3.92B 168B
Net Debt 1.34B 1.16B 1.09B 996M 1.87B 128B 1.9B 12.74B 5B 64.11B 5.05B 4.94B 212B 320M 276M 258M 237M 445M 30.41B 452M 3.03B 1.19B 15.24B 1.2B 1.17B 50.39B
Logo Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Employees
423
Date Price Change Volume
26-08-07 US$103.12 +20.24% 7,691,625
26-08-06 US$85.76 +2.60% 2,704,018
26-08-05 US$83.59 +0.43% 1,262,674
26-08-04 US$83.23 +1.17% 1,574,572
26-08-03 US$82.27 -0.33% 1,367,693
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
103.12USD
Average target price
97.33USD
Spread / Average Target
-5.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HALO Stock